

## SMALL-MOLECULE INHIBITORS OF ANGIOGENESIS

### SUMMARY

The National Cancer Institute's Angiogenesis Core Facility seek parties interested in in-licensing a new set of non-cytotoxic antiangiogenic small molecules.

### REFERENCE NUMBER

E-263-2009

### PRODUCT TYPE

- Therapeutics

### KEYWORDS

- antiangiogenic
- Angiogenesis
- age-related macular degeneration, diabetic retinopathy, endometriosis

### COLLABORATION OPPORTUNITY

This invention is available for licensing.

### CONTACT

John D. Hewes  
NCI - National Cancer Institute  
240-276-5515

[John.Hewes@nih.gov](mailto:John.Hewes@nih.gov)

### DESCRIPTION OF TECHNOLOGY

The [National Cancer Institute's Angiogenesis Core Facility](#) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new set of non-cytotoxic antiangiogenic small molecules.

Angiogenesis, the growth of new blood vessels from existing vessels, is a normal and vital process in growth and development. Deregulation of angiogenesis plays a role in many human diseases, including cancer, age-related macular degeneration, diabetic retinopathy, and endometriosis.

NCI investigators have used a cell-based high-throughput screening method to identify a set of anti-angiogenic small molecules. These compounds are highly active, inhibiting both endothelial cell growth and tube formation, and are not cytotoxic. Structure-activity relationship analysis has revealed that these compounds are unrelated to known anti-angiogenic compounds, and hence may operate through a novel mechanism of action. Thus, these compounds would be promising candidates for the development

of new anti-angiogenesis therapeutics.

#### **POTENTIAL COMMERCIAL APPLICATIONS**

- Development of new anti-angiogenesis therapeutics.

#### **COMPETITIVE ADVANTAGES**

- These compounds are structurally unrelated to other known anti-angiogenesis compounds, and exhibit high activity without cytotoxicity.

#### **INVENTOR(S)**

Enrique Zudaire Ubani, Frank Cuttitta, Marta Aparico (all formerly of NCI)

#### **DEVELOPMENT STAGE**

- Pre-clinical (in vivo)

#### **PATENT STATUS**

- **U.S. Issued:** US 9,186,365 (17 Nov. 2015)
- **Foreign Issued:** JP 5886743 (19 Feb. 2016)

#### **RELATED TECHNOLOGIES**

- [E-281-2007](#)

#### **THERAPEUTIC AREA**

- Cancer/Neoplasm